56 results about "Carcinomatoses" patented technology

Disclosed herein are methods for profiling a cancerous tumor using a high-throughput sequencing technique.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Pharmaceutical compositions including one or more integrin activators capable of capable of improving the anti-cancer activity of nature t-cells, wherein the integrin activators target integrins including, but not limited to, α4β1, α4β7, α5β1, αLβ2 and / or αVβ3 improving binding to their respective ligands including, but not limited to, VCAM-1, fibronectin, MAdCAM-1, ICAM-1, ICAM-2, and / or vitronectin, wherein the compositions treat, ameliorate, and / or reduce symptoms of diseases, maladies, and cancers, and methods for making and using for preventing, treating, ameliorating, and / or reducing symptoms of cancerous tumors, cancerous solid tumors, other cancerous growth, and / or other cancerous.

Provided is a coordination compound represented by formula (I). Also provided is a pharmaceutical composition that can be used to treat cancers, including the coordination compound of formula (I) and a pharmaceutically acceptable carrier. Also provided are applications of the coordination compound in inhibiting cancer cell survival or proliferation, inhibiting cancer cell migration or invasion, and treating cancerous tumors in a subject in need.

The present disclosure provides compositions and methods for distinguishing between non-cancerous, pre-cancerous, and cancerous conditions in the esophagus. In particular, the present disclosure provides compositions and methods for distinguishing non-dysplastic Barrett's esophagus (NDBE) samples from pre-cancerous (e.g., low-grade or high-grade dysplasia) and / or cancerous (e.g., esophageal adenocarcinoma) samples based on methylation status and / or DNA copy number abnormalities.

The present invention describes novel drug-carrying nanoparticles called bionanocarriers capable of modulating the cellular redox system and targeting the cancerous tumor.Specifically, the invention relates to a nanomedicine strategy for combating cancerous tumor cells, a strategy that aims to target the tumor, and consists of providing quercetin-linked magnetite nanoparticles (Q): (MNPs Q), and 3,5-dimaleylbenzoic acid-linked magnetite nanoparticles (A3'5DMB): (MNPs A3'5DMB)M; both types of nanoparticles were subsequently encapsulated with chitosan (Qs) and O-carboxymethyl chitosan (O-CMQs), functionalized with 11-mercaptoundecanoic acid (MUDA), and finally the anti-ABCC3 antibody was attached to the polymer phase, which was used as a selective driver of the delivery process of the encapsulated nanoparticles, thus carrying out the construction of the bionanocarriers: BNC-1: MNPs-Q-Ab; BNC-2: MNPs-a3'5DMB-Ab.Its manufacturing method and the tests of its biological functionality, its stability, the degradation of the encapsulation for the tumor microenvironment, the controlled release profile of the drugs Q and A3'5DMB, selective cell uptake, intracellular localization, cytotoxic effect on steroids of hepatocellular carcinoma cells with altered redox balance and induction of apoptosis, as well as its safety on normal cells, are described.

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and / or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

The invention relates to activity levels for diffusive alpha-emitter radiation therapy. Disclosed herein is a method for treating a cancerous tumor by implanting in the cancerous tumor at least one diffusive alpha-emitter radiation therapy (DaRT) source having a suitable radon release rate and for a given duration, such that the source provides a cumulative activity of released radon per centimeter length of at least 10 megabeel (MBq) hours during a given duration. Optionally, the sources are implanted in the form of an array of sources, each source in the array being spaced from its adjacent source by no more than 4.5 mm.

A method for treating a cancerous tumor by implanting at least one diffusing alpha-emitter radiotherapy (DaRT) source (21) having a suitable radon release rate and for a given duration in the cancerous tumor such that the source (21) provides a cumulative activity of released radon of at least 10 megabecquerel (MBq) hours per centimeter length during the given duration. Optionally, the source (21) is implanted in the form of an array (160) of sources (21) in which each source is spaced no more than 4.5 millimeters from its neighboring sources (21).

Described herein are methods, such as multiomics methods, for assessing diseases, such as cancer. The multi-omics method can integrate proteomic data, transcriptomic data, genomic data, lipidomic data, or metabonomic data. The method screens for a disease or a disease state. Also described herein are methods for screening a disease or a disease state from a biological sample. The method may include assessing whether a nodule, mass, or cyst is cancerous.

Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.

Biomarkers for treatment response and other outcomes in the treatment of lesions, such as cancerous tumors, are derived from routine clinical medical images, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans, using radiomic machine learning techniques. The biomarkers are based, at least in part, on phenotypes derived from vessel morphology features descriptive of vasculature associated with a lesion shown in the medical images and may also include other radiomic and pathomic types of features. The biomarkers and phenotypes may be used at multiple points in the treatment process, and treatment decisions may be based on changes in radiomic features or phenotypes longitudinally through the course of treatment. The biomarkers and phenotypes may also be used in clinical trials, to establish trial parameters, patient enrollment, drug dosage, and other trial parameters.

This invention relates to the field of traditional Chinese medicine preparation technology, and particularly to a traditional Chinese medicine composition for treating cancer pain and numbness, as well as its preparation and application. This invention designs a traditional Chinese medicine composition for cancer pain and numbness, comprising: *Houttuynia cordata*, *Aconitum carmichaelii*, processed *Aconitum carmichaelii*, centipede, *Astragalus membranaceus*, *Ephedra sinica*, clove, frankincense, ephedra, menthol, and azone. The scientifically formulated combination of principal, assistant, and adjuvant herbs allows for multi-target action on both "cancer pain" (inflammation, compression, nerve infiltration) and "CIPN" (nerve damage), resulting in a superior analgesic effect, while also possessing anti-inflammatory, anti-swelling, potential tumor-suppressing, and nerve-repairing effects. The traditional Chinese medicine composition is prepared into a traditional Chinese medicine ointment, which is administered transdermally, allowing a high concentration of the drug to act directly on the lesion, avoiding the systemic side effects (addiction, constipation, etc.) associated with oral opioids. This is especially suitable for patients who cannot take oral opioids or cannot tolerate them.

The present invenon relates to the use of an-BMP4 anbodies in a method for inhibing, prevenng, and treang cancer metastasis in paents. An-BMP4 anbodies have been found to inhibit and even prevent cancer metastasis in paents. These anbodies have also been found to inhibit growth of cancerous metastac cells, thereby treang cancer metastasis.

In an example, one or more implanted tumor temperature sensors may be used in a method to determine an oncological status metric for a patient having one or more cancerous tumors. The tumor temperature measurements are collected, along with a type of cancer and one or more descriptors of a cancer treatment regimen, to calculate the oncological status metric. The oncological status metric is an indicator of cancer treatment efficacy in a patient and may be determined in part, by a programmed algorithm or trained machine learning model.

The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related pathologies, disorders leading to ischemia, and non-cancerous angiogenic diseases.

The subject invention provides organoarsenicals or salts thereof, compositions comprising an organoarsenical or a salt thereof, and methods of using the organoarsenicals or salts thereof, or compositions for inhibiting glutaminase and for treating cancers. Specifically, the subject invention provides methods of inhibiting glutaminase (e.g., KGA) catalytic activity in a cell, methods of treating cancer or a tumor via, for example, the inhibition of glutaminase activity, and methods of disrupting and / or inhibiting growth and proliferation of cancerous or tumorous cells.

The present invention discloses a method for treating cancerous tumours and / or metastasis with MET mutations and / or amplifications using an anti-MET antibody fragment. The method involves administering the antibody fragment, which features a single antigen- binding arm and a silenced Fc region, in effective doses ranging from 350 mg to 5000 mg. This dosage regimen is intended for the effective treatment of cancer, in particular NSCLC.

The present disclosure relates to fusion proteins, such as insulin-Fc fusion proteins, compositions thereof, and their use for treating cancer cells and cancer tumors in subjects in need thereof. After administration, the fusion proteins exhibit anti-tumor effects on the subject's cancer cells, such as downregulation of insulin receptor, downregulation of insulin-like growth factor 1 receptor (IGF1R), reduction of phosphorylated Akt, and combinations thereof. The present disclosure relates to methods for downregulating insulin-like growth factor 1 receptor (IGF1R) in subjects in need thereof, and methods for inhibiting the metabolism, growth, and / or proliferation of cancer cells.

A microwave-based breast cancer screening and early diagnostics imaging system is provided. The microwave-based breast cancer screening and early diagnostics imaging system uses mild compression to electromagnetically homogenize the heterogeneous breast media or, to some degree, decrease the breast dimension to 2D. The device is capable of providing multi-angle examination, if necessary, and produces horizontal and vertical cross-sectional images based on the polarization of the antennas used for scanning. Merging two-sectional images can give a possibility of 3D microwave representation of the breast tissue that allows identification of the malignant / cancerous / harmful tissues / cells through cross validation.

The invention discloses a disposable 700ml limited type puncture drainage bag special for pleural effusion, belongs to the field of clinical medical instruments, and is particularly suitable for drainage of tuberculous pleural effusion and cancerous pleural effusion in a tuberculosis high-incidence area and emergency treatment of war wounds. According to the drainage bag, a special thoracocentesis assembly, an integrated flow control drainage hose and a disposable 700ml pre-filled negative pressure suction bottle are integrated into a sterile integrated kit, the special thoracocentesis assembly comprises a puncture needle with a side hole and a graduated drainage catheter, the middle section of the drainage hose is provided with an integrated buckle clamp, 700ml graduation lines are calibrated by the suction bottle, negative pressure of-0.04 MPa to-0.06 MPa is pre-filled, and the disposable 700ml pre-filled negative pressure suction bottle is provided with a drainage tube. Seamless butt joint is achieved through a Luer taper. The disposable design completely eradicates mycobacterium tuberculosis cross infection, rapid butt joint adapts to battle wound first aid, multi-time flow control meets the cancerous hydrothorax treatment requirement, additional transfer is not needed, unpacking and instant use are achieved, operation is convenient, safety is high, cost is low, and the device is suitable for all levels of medical institutions, grassroots units, field first aid and other scenes and has wide application prospects. The kit is especially suitable for large-scale clinical application in tuberculosis high-incidence areas, and the popularization value is remarkable.

The invention relates to activity levels for diffusive alpha-emitter radiation therapy. Disclosed herein is a method for treating a cancerous tumor by implanting in the cancerous tumor at least one diffusive alpha-emitter radiation therapy (DaRT) source having a suitable radon release rate and for a given duration, such that the source provides a cumulative activity of released radon per centimeter length of at least 10 megabeel (MBq) hours during a given duration. Optionally, the sources are implanted in the form of an array of sources, each source in the array being spaced from its adjacent source by no more than 4.5 mm.

A nanoparticle for selective transfection of M2 macrophages, the nanoparticle including a lipid phase and a core that contains one or more nucleic acids. The nanoparticle selectively delivers the one or more nucleic acids to M2 macrophages in vitro and in vivo. Also provided is a therapeutic composition that contains a plurality of the nanoparticle described above and a pharmaceutically acceptable excipient. Further provided are methods for selective transfection of M2 macrophages, for converting M2 macrophages into M1 macrophages, and for treating a cancerous tumor. The methods are carried out by contacting M2 macrophages with a composition that includes a plurality of the nanoparticle mentioned above.

Provided here are artificial intelligence-driven methods and systems for cancer detection, monitoring of treatment, or prognosis based on evaluation of nuclear lamina wrinkling of the cells in a tissue sample. In an embodiment, such a method may include providing a lamin-stained image of cells in a sample from a subject to a computer-implemented deep learning model. The method may include analyzing a degree of wrinkling of nuclear laminar of the cells with the deep learning model to generate a classification of the cells as cancerous or non-cancerous or of a particular grade; and communicating the classification to a user interface.

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and / or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

A conjugate comprising (a) at least two or more binding motifs, each of which binds a different cell-surface molecule which is overexpressed or selectively expressed on a diseased (e.g., cancerous) cell, wherein adjacent binding motifs are separated from each other by a linker, which can be the same or different as a linker between other adjacent binding motifs, and (b) an active agent, which can be endocytosed by a cancerous cell to which the conjugate binds; a composition comprising the conjugate and a pharmaceutically acceptable carrier, a method of selectively targeting a cancerous cell in a subject for endocytosis of an anti-cancer agent; and a method of imaging a subject with cancer.

A cancer screening method takes advantage of the Warburg Effect to provide an early detection method and system. The cancer screening method includes administering a glucose solution, such as a C-13 glucose solution, measuring a metabolized lactate level in the blood of the individual after a period of time following the administration of the glucose solution, and comparing the measured lactate level to a baseline lactate level representative of noncancerous activity, and making a determination as to whether or not the measured lactate level is potentially indicative of cancer activity in the individual. The period of time is selected to be an amount of time following the glucose administration after which metabolized lactate from cancerous cells would be present in the blood and before which the metabolized lactate would be cleared or substantial amounts of non-cancerous metabolized lactate would be present in the blood of the individual.

A new class of multi-functional lipid nanoparticles comprising a fluoropyrimidine-based therapeutic and a combination of helper lipids is disclosed. The disclosed lipid nanoparticles are formulated for efficient delivery of therapeutic agents to target cells and can be used in the treatment of cancers, including colorectal cancer. The disclosed lipid nanoparticles exhibit improved cellular uptake and increased toxicity to cancerous cells compared to free- fluoropyrimidine therapeutic and other conventional therapeutics. A method for treating cancer by administering the disclosed lipid nanoparticles is also disclosed herein.

The invention discloses a construction method and application of an asbestos-caused lung carcinoma-in-situ animal model, and belongs to the technical field of biomedicine. The construction method comprises the following steps: firstly, carrying out multiple poisoning treatments on embryo fibroblasts by chrysotile, and then carrying out malignant transformation to obtain malignant transformed cells; a luciferase gene is introduced by utilizing lentivirus transfection; and injecting the successfully transfected malignant transformed cells into the lung of an experimental animal by adopting an intrapulmonary injection method, and feeding to obtain the lung carcinoma-in-situ animal model. The method creatively uses asbestos to induce malignant transformed embryo fibroblasts with cancerous characteristics to establish the lung in-situ cancer animal model, and has the advantages of short modeling period, high tumor formation rate, visualized cell transfer condition, capability of better reflecting the cancerous characteristics of asbestos and the like. The constructed model can be applied to clinical diagnosis and treatment research such as pathogenesis research and drug screening evaluation.